Iredale J P, Hooi L M, Kerr K M, Sudlow M F, Wathen C G
Department of Respiratory Medicine, Rayne Laboratory, City Hospital, UK.
Respiration. 1991;58(2):77-80. doi: 10.1159/000195901.
Twenty-five patients with histologically proven small cell lung cancer who were in too poor physical condition to receive 'aggressive' chemotherapy were treated with vindesine and etoposide (VE). The median survival was 195 days, and there were 4 survivors of greater than 460 days. Eight patients died before the second pulse of chemotherapy, and these all had a Karnofsky score of less than or equal to 20 at diagnosis. Toxicity of the chemotherapy regimen was minimal, and the results suggest that VE chemotherapy may be suitable for the treatment of patients with small cell lung cancer who are unsuitable for more toxic chemotherapy.
25例经组织学证实为小细胞肺癌且身体状况太差无法接受“积极”化疗的患者接受了长春地辛和依托泊苷（VE）治疗。中位生存期为195天，有4例生存期超过460天。8例患者在第二次化疗脉冲前死亡，这些患者在诊断时卡氏评分均小于或等于20。化疗方案的毒性极小，结果表明VE化疗可能适用于不适合毒性更强化疗的小细胞肺癌患者的治疗。
